July 01, 2026

Abbisko and AstraZeneca Collaborate on Phase 1/2 Trial of Lumipodlin Plus TAGRISSO in EGFR-Mutant NSCLC

Abbisko Therapeutics and AstraZeneca have entered a strategic collaboration to run a multicenter, open-label P1/2 clinical study of lumipodlin (ABSK043) + TAGRISSO (osimertinib), for EGFR‑mutated, PD‑L1-positive locally advanced or metastatic NSCLC. The study, cleared as an IND by China’s NMPA on May 20, 2026, will evaluate safety and efficacy of this IO-TKI combination, with Abbisko leading the P2 portion and both companies sharing trial responsibilities. Lumipodlin, developed and wholly owned by Abbisko, selectively binds PD‑L1, induces its internalization, and blocks PD‑1/PD‑L1 interaction; in preclinical models it has shown anti‑tumor activity comparable to approved PD‑L1 antibodies, and is already in ongoing P1 study in advanced solid tumors in Australia and China. The collaboration is aimed at addressing the unmet need in EGFR‑mutated NSCLC patients with high PD‑L1 expression, who tend to benefit less from EGFR‑TKIs alone, by offering a potentially differentiated oral PD‑L1 plus third‑generation EGFR‑TKI regimen.

Source: PR Newswire PR Jul 01, 2026

July 04, 2026

Sanyou Bio and Baiyunshan Xihe Partner to Advance Next-Generation Radiopharmaceuticals

Sanyou Bio and Baiyunshan Xihe entered into a strategic collaboration for the co-development of innovative radiopharmaceuticals and radiodiagnostic products for precision oncology. The partnership brings together Sanyou Bio’s AI-driven antibody and targeting molecule discovery platforms (AI-STAL and SAI-DA) and Baiyunshan Xihe’s capabilities in radionuclide production, GMP manufacturing and clinical translation to create an end-to-end development platform encompassing target discovery, radiolabeling, preclinical evaluation and clinical advancement. The companies aim to accelerate the development of differentiated theranostic radiopharmaceuticals using key medical radionuclides, including Ga68, Zr89, Cu64 & Rh186, and reduce development timelines through an integrated AI-enabled R&D approach. The collaboration also aims to boost China’s radiopharmaceutical innovation ecosystem and enhance global competitiveness in precision oncology diagnostics and targeted radiotherapy.

Source: PR Newswire PR Jul 04, 2026

July 06, 2026

Vertex to Acquire Crinetics Pharmaceuticals in $10B Deal to Expand Endocrinology Portfolio

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all-cash transaction valuing Crinetics at about $10B, offering $85 per share, which represents roughly a 102% premium to Crinetics’ prior close and drove Crinetics’ stock to double in extended trading while Vertex’s shares fell modestly. The deal is intended to diversify Vertex beyond its dominant cystic fibrosis franchise by adding a fifth vertical, endocrinology, anchored by Palsonify, the first once-daily oral FDA‑approved therapy for adults with acromegaly and by atumelnant, a late‑stage candidate for congenital adrenal hyperplasia, with the companies projecting more than $5B in potential peak annual sales from Crinetics’ portfolio. Vertex aims to complete the transaction in the Q3 2026 and anticipates that it will start adding positively to adjusted operating income by 2029.

Source: US News PR Jul 06, 2026

July 08, 2026

Tarsus Acquires iRenix Medical to Expand into Retina with Late-Stage Ocular Antiseptic IRX-101

Tarsus acquired iRenix Medical and its late‑stage investigational ocular antiseptic IRX‑101 to expand its leadership in eye care and enter the retina market. IRX‑101 is a stable aqueous chlorine dioxide-based ocular antiseptic being developed to reduce post‑procedural pain and corneal toxicity in patients receiving intravitreal therapy. In the P2b/3 RELIEF study (n=154), IRX‑101 achieved statistically significant ~50% relative reduction in post‑procedural pain and ~25% relative reduction in corneal fluorescein staining vs povidone‑iodine (Betadine). Based on FDA feedback, Tarsus plans a P3 study of IRX‑101 vs povidone‑iodine, with enrollment targeted for 1H 2027 and results expected in 2028. Deal terms include about $75M upfront consisting of $37.5M in cash and $37.5M in Tarsus common stock and potential approval and commercial milestones of up to $490M. The acquisition aligns with Tarsus’s strategy to broaden its eyecare portfolio beyond Demodex blepharitis and strengthen its presence in retina therapeutics.

Source: GlobeNewswire PR Jul 08, 2026

July 14, 2026

AstraZeneca Acquires Worldwide Commercialization Rights to Zegfrovy for EGFR Exon20 NSCLC

Dizal has entered into a global exclusive licensing agreement with AstraZeneca granting the company worldwide rights to develop and commercialize Zegfrovy (sunvozertinib), an oral, irreversible EGFR inhibitor for lung cancer. Zegfrovy is currently approved in both the U.S. and China for adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations whose disease has progressed following platinum-based chemotherapy. The drug recently demonstrated positive P3 WU-KONG28 results as a first-line treatment, showing significant clinical benefit over platinum-doublet chemotherapy. Results were presented at ASCO 2026 and simultaneously published in NEJM. Based on these data, supplemental regulatory applications have been submitted to both the U.S. FDA and China’s CDE, with BTD granted by both agencies for the first-line setting. Dizal will receive $600M upfront, up to $900M in development, regulatory, and commercial milestone payments, and tiered royalties on global sales of Zegfrovy. The transaction is expected to close in Q2 2026, subject to customary closing conditions and regulatory approvals.

Source: PR Newswire PR Jul 14, 2026